Cargando…

P1151: BENDAMUSTINE-CONTAINING REGIMENS CAN BE SAFELY USED AS BRIDGING IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

Detalles Bibliográficos
Autores principales:	Garcia-Calvo, Gloria Ines Iacoboni, Navarro, Victor, Lopez, Ana Africa Martin, Bastos Oreiro, Mariana, Rejeski, Kai, Aleksandra Jalowiec, Katarzyna, Amat, Paula, Ortega, Juan Luis Reguera, Blumenberg, Viktoria, Gallur, Laura, Herrero-García, María, Roddie, Claire, Bailen, Rebeca, Benzaquen, Ana, Segura, Cecilia Carmen Carpio, López Corral, Lucía, Hernani, Rafael, Kwon, MI, Martín-Martín, Lourdes, Subklewe, Marion, O’reilly6, Maeve, Barba Suñol, Pere
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431081/ http://dx.doi.org/10.1097/01.HS9.0000971500.48751.b3

Ejemplares similares

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
por: Rejeski, Kai, et al.
Publicado: (2023)

1151. Clinical Characteristics of Persistent Staph Aureus Bacteremia in Children
por: Venturelli, Nicholas, et al.
Publicado: (2021)

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
por: Rejeski, Kai, et al.
Publicado: (2022)

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2021)

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
por: Kwon, Mi, et al.
Publicado: (2022)

1151 Geographic Distances Between Patients and Providers for Hepatitis C Virus Infection Testing
por: Klevens, Monina, et al.
Publicado: (2014)

1151. Candida Colonization Alters Pathogenic Pulmonary Infection in Pediatric Patients with Cystic Fibrosis
por: Parsons, Emily, et al.
Publicado: (2020)

SG-APSIC1151: ZeBox: A prophylactic device against airborne infection
por: Venkatraman, Srividya Janani, et al.
Publicado: (2023)

Immunological reactions induced by bendamustine
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
por: Bastos-Oreiro, Mariana, et al.
Publicado: (2022)

1151. A Safer, More Effective Method for Cleaning and Disinfecting GI Endoscopic Procedure Rooms
por: Overholt, Bergein, et al.
Publicado: (2018)

P1151: METABOLIC TUMOR VOLUME IMPROVES OUTCOME PREDICTION IN UNTREATED MANTLE CELL LYMPHOMA
por: Vergote, V. K., et al.
Publicado: (2022)

1151. Assessing Vaccine Hesitancy and Logistical Barriers to Undergraduate Students Receiving a Flu Vaccine
por: Benzaken, Casey, et al.
Publicado: (2023)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
por: Robak, Tadeusz, et al.
Publicado: (2016)

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
por: Blumenberg, Viktoria, et al.
Publicado: (2023)

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2022)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
por: Grigg, Andrew, et al.
Publicado: (2017)

Physics Run Analysis No. 2, 1980, Run 1111 (11th April) to 1151 (18th August 1980)
por: Verbeeck, T
Publicado: (1980)

Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol
por: Abkur, Tarig Mohammed, et al.
Publicado: (2015)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION OF AN IDENTICAL PRODUCT: HOST ENVIRONMENT AND DISEASE CHARACTERISTICS DETERMINE THE OUTCOME OF TREATMENT
por: Frölich, L., et al.
Publicado: (2022)

P1445: MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR CARS AND BITES INCREASES GUIDELINE ACCESSIBILITY AND REDUCES TIME TO APPLY EVIDENCE-BASED PATIENT CARE
por: Blumenberg, V., et al.
Publicado: (2022)

Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo.
por: Kurokawa, M, et al.
Publicado: (2001)

Long-Chain Acylcarnitines Decrease the Phosphorylation of the Insulin Receptor at Tyr1151 Through a PTP1B-Dependent Mechanism
por: Vilks, Karlis, et al.
Publicado: (2021)

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
por: Pott, Christiane, et al.
Publicado: (2019)

Bendamustine in the treatment of non-Hodgkin’s lymphomas
por: Hagemeister, Fredrick, et al.
Publicado: (2009)

Bendamustine Associated with Irreversible Ascending Paralysis
por: Alhafez, Ashraf, et al.
Publicado: (2013)

Lichenoid drug eruption associated with Bendamustine
por: Kusano, Y, et al.
Publicado: (2016)

Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
por: Kobayashi, Takashi, et al.
Publicado: (2021)

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update
por: Cheson, Bruce D., et al.
Publicado: (2016)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Role of bendamustine in the treatment of chronic lymphocytic leukemia
por: Jamshed, Saad, et al.
Publicado: (2009)

Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites
por: Darwish, Mona, et al.
Publicado: (2015)

Herpetic esophagitis following bendamustine-containing regimen
por: Yamane, Hiromichi, et al.
Publicado: (2016)

Inhibition of STAT3 by Anticancer Drug Bendamustine
por: Iwamoto, Kazunori, et al.
Publicado: (2017)

Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation
por: Stokes, Jessica, et al.
Publicado: (2021)

Reduced bendamustine for elderly patients with follicular lymphoma
por: Masamoto, Yosuke, et al.
Publicado: (2021)

Bendamustine and pneumocystis pneumonia: A systematic review
por: Hakamifard, Atousa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jmpoe06olou3v1gfvd86golo9g